BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Solera JT, Árbol BG, Alshahrani A, Bahinskaya I, Marks N, Humar A, Kumar D. Impact of Vaccination and Early Monoclonal Antibody Therapy on Coronavirus Disease 2019 Outcomes in Organ Transplant Recipients During the Omicron Wave. Clin Infect Dis 2022;75:2193-200. [PMID: 35445690 DOI: 10.1093/cid/ciac324] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Aggarwal NR, Beaty LE, Bennett TD, Carlson NE, Mayer DA, Molina KC, Peers JL, Russell S, Wynia MK, Ginde AA. Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase. Int J Infect Dis 2022;128:310-7. [PMID: 36229005 DOI: 10.1016/j.ijid.2022.10.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
2 Yetmar ZA, Razonable RR. No patient left behind: A multilayered approach to mitigate COVID-19 in transplant recipients. Transpl Infect Dis 2023;:e13956. [PMID: 36689293 DOI: 10.1111/tid.13956] [Reference Citation Analysis]
3 Herting A, Jahnke-triankowski J, Harberts A, Schaub GM, Lütgehetmann M, Ruether DF, Fischer L, Addo MM, Lohse AW, Schulze zur Wiesch J, Sterneck M. Clinical Outcomes of SARS-CoV-2 Breakthrough Infections in Liver Transplant Recipients during the Omicron Wave. Viruses 2023;15:297. [DOI: 10.3390/v15020297] [Reference Citation Analysis]
4 Rasmussen LD, Lebech AM, Øvrehus A, Poulsen BK, Christensen HR, Nielsen H, Johansen IS, Omland LH, Wiese L, Helleberg M, Storgaard M, Dalager-Pedersen M, Rasmussen TA, Benfield T, Petersen TS, Andersen ÅB, Gram MA, Stegger M, Edslev SM, Obel N. Experience with sotrovimab treatment of SARS-CoV-2-infected patients in Denmark. Br J Clin Pharmacol 2022. [PMID: 36519217 DOI: 10.1111/bcp.15644] [Reference Citation Analysis]
5 Alshukairi AN, Aldabbagh Y, Adroub SA, Mourier T, Abumelha KY, Albishi GE, Alraddadi BM, Al Hroub MK, El-Saed A, Ibrahim SMN, Al Musawa M, Almasari A, Habahab WT, Alhamlan FS, Al-Omari A, Pain A, Dada A. Outcome of Transplant Recipients Infected with Omicron BA.1 and BA.2: A Single-Center Retrospective Study in Saudi Arabia. J Epidemiol Glob Health 2023;:1-8. [PMID: 36626091 DOI: 10.1007/s44197-023-00084-6] [Reference Citation Analysis]
6 Green ACA, Curtis HJ, Higgins R, Nab L, Mahalingasivam V, Smith RM, Mehrkar A, Inglesby P, Drysdale H, Devito NJ, Croker R, Rentsch CT, Bhaskaran K, Tazare J, Zheng B, Andrews CD, Bacon SCJ, Davy S, Dillingham I, Evans D, Fisher L, Hickman G, Hopcroft LEM, Hulme WJ, Massey J, Macdonald O, Morley J, Morton CE, Park RY, Walker AJ, Ward T, Wiedemann M, Bates C, Cockburn J, Parry J, Hester F, Harper S, Douglas IJ, Evans SJW, Goldacre B, Tomlinson LA, Mackenna B. Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY. bmjmed 2023;2:e000276. [DOI: 10.1136/bmjmed-2022-000276] [Reference Citation Analysis]
7 Solera JT, Árbol BG, Bahinskaya I, Marks N, Humar A, Kumar D. Short-course early outpatient remdesivir prevents severe disease due to COVID-19 in organ transplant recipients during the omicron BA.2 wave. Am J Transplant 2023;23:78-83. [PMID: 36148607 DOI: 10.1111/ajt.17199] [Reference Citation Analysis]
8 Farhadian N, Farhadian M, Zamanian MH, Taghadosi M, Vaziri S. Sotrovimab therapy in solid organ transplant recipients with mild to moderate COVID-19: a systematic review and meta-analysis. Immunopharmacology and Immunotoxicology 2022. [DOI: 10.1080/08923973.2022.2160733] [Reference Citation Analysis]
9 Pinargote-Celorio H, Otero-Rodríguez S, González-de-la-Aleja P, Rodríguez-Díaz JC, Climent E, Chico-Sánchez P, Riera G, Llorens P, Aparicio M, Montiel I, Boix V, Moreno-Pérez Ó, Ramos-Rincón JM, Merino E. [Mild SARS-CoV-2 infection in vulnerable patients: implementation of a clinical pathway for early treatment]. Enferm Infecc Microbiol Clin 2022. [PMID: 36506459 DOI: 10.1016/j.eimc.2022.11.004] [Reference Citation Analysis]
10 Kodali L, Budhiraja P, Gea-Banacloche J. COVID-19 in kidney transplantation-implications for immunosuppression and vaccination. Front Med (Lausanne) 2022;9:1060265. [PMID: 36507509 DOI: 10.3389/fmed.2022.1060265] [Reference Citation Analysis]
11 Amani B, Amani B. Efficacy and safety of sotrovimab in patients with COVID-19: A rapid review and meta-analysis. Rev Med Virol 2022;32:e2402. [PMID: 36226323 DOI: 10.1002/rmv.2402] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Chen X, Wang H, Ai J, Shen L, Lin K, Yuan G, Sheng X, Jin X, Deng Z, Xu J, Lu G, Chen S, Cai J, Zhang Y, Zhang H, Wang S, Zhang W, Fan C. Identification of CKD, bedridden history and cancer as higher-risk comorbidities and their impact on prognosis of hospitalized Omicron patients: a multi-center cohort study. Emerging Microbes & Infections. [DOI: 10.1080/22221751.2022.2122581] [Reference Citation Analysis]
13 Aggarwal NR, Beaty LE, Bennett TD, Carlson NE, Ginde AA. Change in Effectiveness of Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients During the Omicron Phase.. [DOI: 10.1101/2022.06.17.22276575] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]